PillRx only · Tablet, Film Coated · Oral
Velpatasvir And Sofosbuvir
Brands: Epclusa · Sofosbuvir And Velpatasvir · Sofosbuvir + Velpatasvir
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US3 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$572.061
Latest avg · Jul 22, 2026
-0%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
19K
Rx · 2026 Q1
550K
Units dispensed
-21%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Gilead Sciences, Inc. | unknown | 2 | SUPPLYING |
| Asegua Therapeutics LLC | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Mar 7, 2025RECALLRecall (Class II): Sofosbuvir and Velpatasvir, 400 mg/100 mg tablets, 28 tablets: 2x14 blister cards, Rx Only, Manufactured for: Asegua Th…
Defective Container: blister packs not properly sealed resulting in tablets being loose in the carton. — Recalling firm: ASEGUA THERAPEUTICS LLC — US Nationwide